Who is sponsoring NCT05921344?

NCT05921344 is sponsored by Shanghai Jiao Tong University School of Medicine.

What condition does NCT05921344 study?

NCT05921344 studies Type 2 Diabetes, Medical Device.

Is NCT05921344 still recruiting?

NCT05921344 is currently completed. Last updated 5 February 2025.

Last reviewed 2025-02-05 · How we verify

NCT05921344

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preclinical Research of mμSORS for Noninvasive Blood Glucose Detection

Completed NA Last updated 5 February 2025

What this trial tests

NA trial testing Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection in Type 2 Diabetes in 200 participants. Completed in 10 October 2023.

Timeline

11 July 2023

Primary endpoint
19 September 2023

10 October 2023

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	200
Start date	11 July 2023
Primary completion	19 September 2023
Estimated completion	10 October 2023
Sites	1 location across China

Drugs / interventions tested

Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Medical Device — all drugs for Medical Device →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

18 and older, any sex, with Type 2 Diabetes or Medical Device. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, prospective study. Blood glucose was measured at different time points during oral glucose tolerance testing in patients with type 2 diabetes mellitus, using both venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). Venous plasma glucose was set as gold standard.The two measurements were collected synchronously so as to calculate the mean absolute relative difference (MARD) and the consensus error grid (CEG). Accuracy of non-invasive blood glucose testing by mμSORS will be validated. MARD for two measurement methods in different blood glucose ranges and the safety outcomes of mμSORS such as adverse events will also be assessed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Assessment of Optical Attenuation and Skin Thickness in Type 2 Diabetes Mellitus Patients Using Optical Coherence Tomography.
Chen M, Shen Y, Zhu J, Su T, et al · · 2024 · cited 2× · PMID 39438766 · DOI 10.1002/jbio.202400267

Verify or expand the search:

Other trials of Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection

Trials testing the same drug.

NCT06512077 — Clinical Validation of mμSORS for Non-invasive Blood Glucose Detection in Non-diabetic Subjects · NA · completed
NCT05504005 — Clinical Validation of mμSORS for Noninvasive Blood Glucose Detection · NA · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05921344 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 5 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921344.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing